Literature DB >> 19302997

Serum mesothelin has a higher diagnostic utility than hyaluronic acid in malignant mesothelioma.

Bogdan Grigoriu1, Bachar Chahine, Farid Zerimech, Marc Grégoire, Malika Balduyck, Marie-Christine Copin, Patrick Devos, Philippe Lassalle, Arnaud Scherpereel.   

Abstract

UNLABELLED: We assessed comparatively the diagnostic value of two potential malignant pleural mesothelioma (MPM) markers: hyaluronic acid (HA) and soluble mesothelin. MATERIALS AND
METHOD: We measured serum and pleural fluid values of mesothelin and hyaluronic acid in 76 patients with MPM, 33 patients with pleural metastases of carcinomas (Mets group) and 27 patients with benign pleural effusion related to asbestos exposure (BPLAE).
RESULTS: Using a serum HA cut-off of 100 microg/L, 8 patients/33 (24.2%) were positive in the Mets group versus 20/76 (26.3%) in the MPM group and only 1/27 BPLAE patients. The area under ROC curve for serum HA in MPM versus Mets or BPLAE groups was only 0.617 while it was 0.755 for mesothelin. In pleural fluid, both markers had similar diagnostic values.
CONCLUSIONS: Serum mesothelin is more sensitive than hyaluronic acid in diagnosing MPM and there is no benefit in combining both markers.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19302997     DOI: 10.1016/j.clinbiochem.2009.03.007

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  18 in total

Review 1.  What's the place of immunotherapy in malignant mesothelioma treatments?

Authors:  Marc Grégoire
Journal:  Cell Adh Migr       Date:  2010-01-30       Impact factor: 3.405

2.  Identification of novel markers for the diagnosis of malignant pleural mesothelioma.

Authors:  Fabien Gueugnon; Sabrina Leclercq; Christophe Blanquart; Christine Sagan; Laurent Cellerin; Martine Padieu; Christian Perigaud; Arnaud Scherpereel; Marc Gregoire
Journal:  Am J Pathol       Date:  2011-03       Impact factor: 4.307

3.  Evaluation of pleural fluid human epididymis 4 (HE4) as a marker of malignant pleural effusion.

Authors:  Mohamed Y Elsammak; Adel Attia; Hoda A Hassan; Taysser M Zaytoun; Mahmoud Shorman; Moosa Suleman
Journal:  Tumour Biol       Date:  2012-06-09

Review 4.  Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis.

Authors:  Kevin Hollevoet; Johannes B Reitsma; Jenette Creaney; Bogdan D Grigoriu; Bruce W Robinson; Arnaud Scherpereel; Alfonso Cristaudo; Harvey I Pass; Kristiaan Nackaerts; José A Rodríguez Portal; Joachim Schneider; Thomas Muley; Francesca Di Serio; Paul Baas; Marco Tomasetti; Alex J Rai; Jan P van Meerbeeck
Journal:  J Clin Oncol       Date:  2012-03-12       Impact factor: 44.544

5.  A role for the retinoblastoma protein as a regulator of mouse osteoblast cell adhesion: implications for osteogenesis and osteosarcoma formation.

Authors:  Bernadette Sosa-García; Volkan Gunduz; Viviana Vázquez-Rivera; W Douglas Cress; Gabriela Wright; Haikuo Bian; Philip W Hinds; Pedro G Santiago-Cardona
Journal:  PLoS One       Date:  2010-11-11       Impact factor: 3.240

6.  Auto-antibodies to β-F1-ATPase and vimentin in malignant mesothelioma.

Authors:  Jenette Creaney; Ian M Dick; Deborah Yeoman; Sarah Wong; Bruce W S Robinson
Journal:  PLoS One       Date:  2011-10-17       Impact factor: 3.240

7.  Chemokine (C-C motif) ligand 3 detection in the serum of persons exposed to asbestos: A patient-based study.

Authors:  Jiegou Xu; David B Alexander; Masaaki Iigo; Hirokazu Hamano; Satoru Takahashi; Takako Yokoyama; Munehiro Kato; Ikuji Usami; Takeshi Tokuyama; Masahiro Tsutsumi; Mouka Tamura; Tetsuya Oguri; Akio Niimi; Yoshimitsu Hayashi; Yoshifumi Yokoyama; Ken Tonegawa; Katsumi Fukamachi; Mitsuru Futakuchi; Yuto Sakai; Masumi Suzui; Michihiro Kamijima; Naomi Hisanaga; Toyonori Omori; Dai Nakae; Akihiko Hirose; Jun Kanno; Hiroyuki Tsuda
Journal:  Cancer Sci       Date:  2015-06-05       Impact factor: 6.716

8.  Hyaluronan and N-ERC/mesothelin as key biomarkers in a specific two-step model to predict pleural malignant mesothelioma.

Authors:  Filip Mundt; Gustav Nilsonne; Sertaç Arslan; Karola Csürös; Gunnar Hillerdal; Huseyin Yildirim; Muzaffer Metintas; Katalin Dobra; Anders Hjerpe
Journal:  PLoS One       Date:  2013-08-21       Impact factor: 3.240

9.  Proteome screening of pleural effusions identifies galectin 1 as a diagnostic biomarker and highlights several prognostic biomarkers for malignant mesothelioma.

Authors:  Filip Mundt; Henrik J Johansson; Jenny Forshed; Sertaç Arslan; Muzaffer Metintas; Katalin Dobra; Janne Lehtiö; Anders Hjerpe
Journal:  Mol Cell Proteomics       Date:  2013-12-20       Impact factor: 5.911

10.  Biomarkers for early detection of malignant mesothelioma: diagnostic and therapeutic application.

Authors:  Marco Tomasetti; Lory Santarelli
Journal:  Cancers (Basel)       Date:  2010-04-14       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.